Characteristics of α 1 ‐adrenoceptor antagonists‐induced ejaculatory dysfunction on spontaneous seminal emission in rats
Basic & Clinical Pharmacology & Toxicology · 2024
DOI: 10.1111/bcpt.13993 ↗At a glance
Journal article in Basic & Clinical Pharmacology & Toxicology, 2024. Written by Masaru Yoshizumi and 5 co-authors. Institution: Division of Physiology and Anatomy, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan. Major MEDLINE topics: Adrenergic alpha-1 Receptor Antagonists, Ejaculatory Dysfunction, Naphthalenes, Piperazines. Cited 1 times so far (Crossref); 35 references. Funded by: JSPS KAKENHI, Japan Society for the Promotion of Science.
Abstract (original language)
Although α 1 ‐adrenoceptor (α 1 ‐AR) antagonists used to treat benign prostatic hyperplasia can cause ejaculation disorders, the aetiology of this adverse event is still controversial. Therefore, we investigated the effects of antagonists with different affinities for α 1 ‐AR subtypes on ejaculatory function and their mechanisms of action in normal rats. In the spontaneous seminal emission (SSE) test, systemically administered prazosin, terazosin, tamsulosin and naftopidil decreased the weight of ejaculated seminal material in a dose‐dependent manner; the potency order was as follows: tamsulosin > terazosin > prazosin > naftopidil. The selective α 1D ‐AR antagonist BMY7378 had no effect on SSE. Intrathecal tamsulosin and naftopidil did not inhibit SSE. Tamsulosin, the most potent, was ineffective as a single dose and significantly increased seminal vesicle fluid in rats treated for 2 weeks but did not significantly change retrograde ejaculation. These results indicated that the difference in inhibitory potency of the five α 1 ‐AR antagonists against SSE was due to the involvement of α 1A ‐AR subtypes. Our results further suggested that α 1 ‐AR antagonist‐induced ejaculatory dysfunction at the peripheral level was mainly due to the loss of seminal emission, although some retrograde ejaculation may also be involved.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Physiology and Anatomy, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
- Division of Pharmaceutical Center, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
ORCID profiles: Masaru Yoshizumi
Funding
- JSPS KAKENHI
- Japan Society for the Promotion of Science
Cite
APA
Yoshizumi, M., Ise, S. N., Yonezawa, A., Watanabe, C., Sakurada, S., & Mizoguchi, H. (2024). Characteristics of α 1 ‐adrenoceptor antagonists‐induced ejaculatory dysfunction on spontaneous seminal emission in rats. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13993
Vancouver
Yoshizumi M, Ise SN, Yonezawa A, Watanabe C, Sakurada S, Mizoguchi H. Characteristics of α 1 ‐adrenoceptor antagonists‐induced ejaculatory dysfunction on spontaneous seminal emission in rats. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.13993
BibTeX
@article{Yoshizumi2024,
author = {Yoshizumi, Masaru and Ise, Shin-Nosuke and Yonezawa, Akihiko and Watanabe, Chizuko and Sakurada, Shinobu and Mizoguchi, Hirokazu},
title = {Characteristics of α 1 ‐adrenoceptor antagonists‐induced ejaculatory dysfunction on spontaneous seminal emission in rats},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2024},
doi = {10.1111/bcpt.13993}
}
EUVIMED